Taiwan · Delayed Price · Currency is TWD Diamond Biofund Statistics
Total Valuation
Diamond Biofund has a market cap or net worth of TWD 13.78 billion. The enterprise value is 6.64 billion.
| Market Cap | 13.78B |
| Enterprise Value | 6.64B |
Important Dates
The last earnings date was Monday, August 10, 2026.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Diamond Biofund has 853.36 million shares outstanding. The number of shares has increased by 1.17% in one year.
| Current Share Class | 853.36M |
| Shares Outstanding | 853.36M |
| Shares Change (YoY) | +1.17% |
| Shares Change (QoQ) | +1.95% |
| Owned by Insiders (%) | 25.12% |
| Owned by Institutions (%) | 4.38% |
| Float | 176.01M |
Valuation Ratios
The trailing PE ratio is 4.77.
| PE Ratio | 4.77 |
| Forward PE | n/a |
| PS Ratio | 4.56 |
| PB Ratio | 1.12 |
| P/TBV Ratio | 1.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.27 |
| EV / Sales | 2.20 |
| EV / EBITDA | 2.29 |
| EV / EBIT | 2.31 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 104.29, with a Debt / Equity ratio of 0.01.
| Current Ratio | 104.29 |
| Quick Ratio | 104.24 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | -0.28 |
| Interest Coverage | 1,054.08 |
Financial Efficiency
Return on equity (ROE) is 26.97% and return on invested capital (ROIC) is 55.39%.
| Return on Equity (ROE) | 26.97% |
| Return on Assets (ROA) | 16.38% |
| Return on Invested Capital (ROIC) | 55.39% |
| Return on Capital Employed (ROCE) | 23.26% |
| Weighted Average Cost of Capital (WACC) | 9.43% |
| Revenue Per Employee | 104.27M |
| Profits Per Employee | 100.82M |
| Employee Count | 29 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.46% in the last 52 weeks. The beta is 0.95, so Diamond Biofund's price volatility has been similar to the market average.
| Beta (5Y) | 0.95 |
| 52-Week Price Change | -23.46% |
| 50-Day Moving Average | 17.57 |
| 200-Day Moving Average | 16.11 |
| Relative Strength Index (RSI) | 44.16 |
| Average Volume (20 Days) | 2,323,087 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diamond Biofund had revenue of TWD 3.02 billion and earned 2.92 billion in profits. Earnings per share was 3.39.
| Revenue | 3.02B |
| Gross Profit | 3.02B |
| Operating Income | 2.88B |
| Pretax Income | 2.92B |
| Net Income | 2.92B |
| EBITDA | 2.88B |
| EBIT | 2.88B |
| Earnings Per Share (EPS) | 3.39 |
Balance Sheet
The company has 7.22 billion in cash and 81.72 million in debt, with a net cash position of 7.14 billion or 8.37 per share.
| Cash & Cash Equivalents | 7.22B |
| Total Debt | 81.72M |
| Net Cash | 7.14B |
| Net Cash Per Share | 8.37 |
| Equity (Book Value) | 12.31B |
| Book Value Per Share | 14.43 |
| Working Capital | 7.17B |
Cash Flow
In the last 12 months, operating cash flow was -290.78 million and capital expenditures -1,000, giving a free cash flow of -290.78 million.
| Operating Cash Flow | -290.78M |
| Capital Expenditures | -1,000 |
| Depreciation & Amortization | 7.18M |
| Net Borrowing | -24.26M |
| Free Cash Flow | -290.78M |
| FCF Per Share | -0.34 |
Margins
Gross margin is 100.00%, with operating and profit margins of 95.13% and 96.70%.
| Gross Margin | 100.00% |
| Operating Margin | 95.13% |
| Pretax Margin | 96.70% |
| Profit Margin | 96.70% |
| EBITDA Margin | 95.37% |
| EBIT Margin | 95.13% |
| FCF Margin | n/a |
Dividends & Yields
Diamond Biofund does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.17% |
| Shareholder Yield | -1.17% |
| Earnings Yield | 21.22% |
| FCF Yield | -2.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 7, 2023. It was a forward split with a ratio of 1.18.
| Last Split Date | Aug 7, 2023 |
| Split Type | Forward |
| Split Ratio | 1.18 |
Scores
Diamond Biofund has an Altman Z-Score of 71.43 and a Piotroski F-Score of 3.
| Altman Z-Score | 71.43 |
| Piotroski F-Score | 3 |